Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temuterkib + Ibrutinib in Ibrutinib-Resistant B-cell Malignancies
NCT04043845Phase 1Withdrawn
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2020
- Primary completion
- Feb 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of temuterkib in chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia (WM), mantle cell lymphoma (MCL) and 1 more, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Dose Limiting Toxicity at 42 days. Planned start Feb 2020; status: withdrawn.
02
Drugs
temuterkib
03
Conditions
chronic lymphocytic leukemia (CLL)Waldenstrom macroglobulinemia (WM)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04043845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04043845.